Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$9.21 USD
+0.12 (1.26%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $9.22 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LQDA 9.21 +0.12(1.26%)
Will LQDA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LQDA
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
Other News for LQDA
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Liquidia requests preliminary injunction against FDA for Tyvaso 3-year exclusivity
Liquidia to Present at Upcoming Investor Conferences
Biotech Alert: Searches spiking for these stocks today
Liquidia challenges FDA decision on Yutrepia exclusivity